Drug maker Taiwan Liposome Co (TLC, 台灣微脂體) yesterday said that it has approval from the Chinese government to begin second-phase clinical trials for its new liver cancer treatment, paving the way for the company to complete the first stage of second-phase trials early next year.
The company is currently undergoing phase two trials for the drug — Lipotecan — in Taiwan, and the approval will expedite the process by allowing the company to recruit patients on both sides of the Taiwan Strait, the company said.
After the company completes the trials early next year, it plans to license the drug to other companies or invite new partners to conduct further trials together, it said.
“The phase two trials are to test whether Lipotecan can extend the overall survival of patients who develop drug resistance to first-line liver cancer drug Nexavar to more than three months,” a company official, who declined to be named, said in a telephone interview.
Surgical resection is the most commonly used course of treatment for early stage liver cancer, while late stage patients who are not able to have operations take Nexavar, the official said.
Nexavar prolonged overall survival to 10.7 months, compared with 7.9 months for patients taking a placebo, she added.
Taiwan Liposome is also mulling conducting further trials to test whether Lipotecan can replace Nexavar, she said.
Taiwan Liposome set an annual sales target for Lipotecan of between US$150 million and US$200 million in China, while German-based drug maker Bayer AG generated US$150 million a year by selling Nexavar in China, the company said.
Lipotecan is developed by using Taiwan Liposome’s technology to enhance the effectiveness and reduce the side effects of a camptothecin derivative, TLC said.
Taiwan Liposome has to pay less than US$200,000 as milestone payments to the inventor of the camptothecin derivative in the future, the company said, adding that the inventor will also receive single digit royalties from sales of Lipotecan.
There are more than 780,000 new liver cancer patients around the world every year, with half of the patients from China, the official said.
In 2012, out of 746,000 patients who died from the disease, 383,000 of them were Chinese, she added.
Taiwan Liposome shares dropped 3.26 percent to NT$208 yesterday, underperforming the over-the-counter benchmark index, which was down 0.05 percent.
Taiwan Transport and Storage Corp (TTS, 台灣通運倉儲) yesterday unveiled its first electric tractor unit — manufactured by Volvo Trucks — in a ceremony in Taipei, and said the unit would soon be used to transport cement produced by Taiwan Cement Corp (TCC, 台灣水泥). Both TTS and TCC belong to TCC International Holdings Ltd (台泥國際集團). With the electric tractor unit, the Taipei-based cement firm would become the first in Taiwan to use electric vehicles to transport construction materials. TTS chairman Koo Kung-yi (辜公怡), Volvo Trucks vice president of sales and marketing Johan Selven, TCC president Roman Cheng (程耀輝) and Taikoo Motors Group
Among the rows of vibrators, rubber torsos and leather harnesses at a Chinese sex toys exhibition in Shanghai this weekend, the beginnings of an artificial intelligence (AI)-driven shift in the industry quietly pulsed. China manufactures about 70 percent of the world’s sex toys, most of it the “hardware” on display at the fair — whether that be technicolor tentacled dildos or hyper-realistic personalized silicone dolls. Yet smart toys have been rising in popularity for some time. Many major European and US brands already offer tech-enhanced products that can enable long-distance love, monitor well-being and even bring people one step closer to
RECORD-BREAKING: TSMC’s net profit last quarter beat market expectations by expanding 8.9% and it was the best first-quarter profit in the chipmaker’s history Taiwan Semiconductor Manufacturing Co (TSMC, 台積電), which counts Nvidia Corp as a key customer, yesterday said that artificial intelligence (AI) server chip revenue is set to more than double this year from last year amid rising demand. The chipmaker expects the growth momentum to continue in the next five years with an annual compound growth rate of 50 percent, TSMC chief executive officer C.C. Wei (魏哲家) told investors yesterday. By 2028, AI chips’ contribution to revenue would climb to about 20 percent from a percentage in the low teens, Wei said. “Almost all the AI innovators are working with TSMC to address the
Malaysia’s leader yesterday announced plans to build a massive semiconductor design park, aiming to boost the Southeast Asian nation’s role in the global chip industry. A prominent player in the semiconductor industry for decades, Malaysia accounts for an estimated 13 percent of global back-end manufacturing, according to German tech giant Bosch. Now it wants to go beyond production and emerge as a chip design powerhouse too, Malaysian Prime Minister Anwar Ibrahim said. “I am pleased to announce the largest IC (integrated circuit) Design Park in Southeast Asia, that will house world-class anchor tenants and collaborate with global companies such as Arm [Holdings PLC],”